02.20.2018
Crohn's Disease
$749,291.00
24 months
Formation of a Pre-consortium Focused on Identification and Prioritization of Fluid Biomarkers for Crohn's Disease
The lack of regulatory endorsed biomarkers in Crohn's disease (CD) diagnostic and personalized medicine has hindered the accelerated development and approval of novel and improved therapeutics for CD patients. This project aims to lay the groundwork for the identification and positioning of high impact biomarkers for regulatory endorsement to benefit patients in need of better therapeutics for the treatment of CD.